MediLink beats Sotio to the punch
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
